Clinical trials: Resectable Pancreatic Cancer
Pancreatic Cancer
Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer
Multicenter Prospective Phase II Study for Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer RATIONALE: Borderline resectable pancreatic cancer is frequently related to a positive surgical…
- Trial name
- NCT02459652
- Testing
- S-1, Radiation Therapy
- Where
- 22 sites in Japan
- Volunteers
- 57 people
- Sponsor
- Japan Adjuvant Study Group of Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer.
- Trial name
- NCT01962909
- Testing
- PTP-01
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Virginia
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
This is a clinical research study of an investigational (FDA BB-IND 10091) treatment for patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer responds to standard therapies.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic, Colorectal Cancer Metastatic
- Trial name
- Macrobead (NCT01053013)
- Testing
- RENCA macrobeads
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- The Rogosin Institute
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant…
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-3 (NCT04927780)
- Testing
- Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride
- Where
- 21 sites in Netherlands, Sweden
- Volunteers
- 378 people
- Sponsor
- Erasmus Medical Center
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight.
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma
- Trial name
- NCT05642962
- Testing
- Pertzye
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma
FAZA PET/MRI Pancreas
This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer
- Trial name
- NCT04395469
- Testing
- 18F-FAZA
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499265
- Testing
- gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671
- Where
- 39 sites in Germany, Hungary and 4 more
- Volunteers
- 95 people
- Sponsor
- Heidelberg Pharma AG
Pancreatic Ductal Adenocarcinoma
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic…
- Trial name
- NCT04969731
- Testing
- Immuncell-LC, Gemcitabine
- Where
- South Korea
- Volunteers
- 408 people
- Sponsor
- GC Cell Corporation
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Curative management of locally resectable invasive adenocarcinomas located in the cephalic region of the pancreas (pancreas, duodenum and ampulla of Vater) requires a pancreaticoduodenectomy followed by adjuvant chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma
- Trial name
- TPIAT-01 (NCT05116072)
- Testing
- total pancreatectomy, intraportal islet autotransplantation
- Where
- France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Lille
Pancreatic Cancer
Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer
To determine the feasibility and toxicity of neoadjuvant hypofractioned radiotherapy concurrently with weekly gemcitabine and an EGFR tyrosine-kinase inhibitor (OSI-774, Tarceva) in the treatment of patients with resectable…
- Trial name
- NCT00243854
- Testing
- Tarceva
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Pancreatic Cancer Non-resectable, Chemotherapy Effect
Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer
In patients diagnosed with locally advanced pancreatic cancer (LAPC)/borderline resectable pancreatic cancer (BRPC) and planned chemotherapy using FOLFIRINOX, high intensity focused ultrasound (HIFU)/FOLFIRINOX combined treatment…
- Conditions
- Pancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound Therapy
- Trial name
- NCT05262452
- Testing
- ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Pancreatic Adenocarcinoma, Pancreatic Cancer
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
This study includes participants with pancreatic cancer who are undergoing genetic testing at Invitae related to their diagnosis of pancreatic cancer. Our goal in this study is two-fold.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Cancer
- Trial name
- ARTEMIS (NCT05380557)
- Testing
- Germline genetic testing
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Invitae Corporation
Pancreatic Cancer, Pancreatic Cancer Non-resectable
Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer
To evaluate the efficacy and safety of surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advance d pancreatic cancer
- Conditions
- Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06361030
- Testing
- surufatinib combined with gemcitabine plus nab-paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastrointestinal Cancers, Frailty
Longitudinal Geriatric Vulnerability, Chemotherapy Toxicity, and Functional Outcomes in Older Adults With Gastrointestinal Cancer
Older adults with gastrointestinal cancers may be more likely to experience side effects from chemotherapy and difficulties with everyday activities. These problems are not always explained by age alone.
- Conditions
- Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly, Malnutrition Elderly
- Trial name
- VITAL-GI (NCT07184047)
- Testing
- Standard-of-Care Systemic Chemotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 132 people
- Sponsor
- Ankara Etlik City Hospital
Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression
This is a non-randomized phase II , open label, comparative study. Patients with advanced non-resectable and/or progressive gastro-entero-pancreatic Neuroendocrine Tumours - GEP-NET, (G1, G2 and G3), Broncho-pulmonary Carcinoids…
- Trial name
- POLNETS_PRRT (NCT04029428)
- Testing
- 90Y-DOTATATE, (177Lu-DOTAOTyr3)Octreotate, 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- University of Warmia and Mazury
Pancreatic Cancer
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00335543
- Testing
- cisplatin, gemcitabine hydrochloride, adjuvant therapy
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 254 people
- Sponsor
- Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft
Resectable Pancreatic Cancer With Biliary Obstruction
A Prospective Randomized Multi-center Study for Efficacy of Metallic Biliary Stent Compared to Plastic Stent in Patients Receiving Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Pancreatic cancer is the eighth most common occurrence in Korea. In the United States, pancreatic cancer is expected to be the number two cause of death from cancer in 2030.
- Trial name
- NCT04911647
- Testing
- ERCP using plastic stent, ERCP using metal stent
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Yonsei University